Anzeige
Mehr »
Login
Samstag, 17.04.2021 Börsentäglich über 12.000 News von 660 internationalen Medien
Überraschende News bei BIOTECH-PERLE!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14R82 ISIN: BE0974281132 Ticker-Symbol: 8XB 
Frankfurt
16.04.21
12:21 Uhr
4,300 Euro
0,000
0,00 %
Branche
Gesundheitswesen
Aktienmarkt
BEL Mid
1-Jahres-Chart
BIOCARTIS GROUP NV Chart 1 Jahr
5-Tage-Chart
BIOCARTIS GROUP NV 5-Tage-Chart
RealtimeGeldBriefZeit
4,3104,41012:38

Aktuelle News zur BIOCARTIS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiBiocartis Group NV: Invitation to the Annual and Extraordinary Shareholders' Meetings1
01.04.Biocartis Group NV: Biocartis Announces Publication of 2020 Annual Report4
BIOCARTIS Aktie jetzt für 0€ handeln
22.03.Biocartis Group NV: Biocartis Launches Idylla GeneFusion Assay as Rapid Lab Workflow Solution for Gene Fusion Testing4
25.02.Biocartis Group NV: BIOCARTIS ANNOUNCES 2020 RESULTS AND 2021 OUTLOOK8
18.02.Biocartis NV: Press news Biocartis Group NV: BIOCARTIS ANNOUNCES 2020 FULL YEAR RESULTS ON 25 FEBRUARY 20213
02.02.Biocartis NV: Press news Biocartis Group NV: New US Studies Demonstrate Idylla Allows Rapid First Assessment of Most Common EGFR Mutations Preceding Next-Generation ...7
29.01.Technavio Research: Influenza Diagnostics Market 2020-2024- Abbott Laboratories, Biocartis Group NV, Bio-Rad Laboratories Inc., Among Others to Contribute to the Market Growth | Industry Analysis, Market Trends, Opportunities and Forecast 2024 | Technavio395The influenza diagnostics market is poised to grow by 1.32 bn during 2020-2024, decelerating at a CAGR of almost 10% during the forecast period. This press release features multimedia. View the full...
► Artikel lesen
11.01.Biocartis NV: Press news Biocartis Group NV: BIOCARTIS MEETS 2020 KEY OBJECTIVES9
17.12.20Biocartis NV: Press news Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES5
07.12.20Biocartis NV: Press news Biocartis Group NV: Biocartis Announces the Conversion of EUR 15 million of its EUR 150 million 4% Convertible Bonds due 20247
24.11.20Biocartis NV: Press news Biocartis Group NV - Regulated Information: Disclosure of a transparency notification6
17.11.20Biocartis NV: Press news Biocartis Group NV: Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla MSI Assay Showing Very ...3
16.11.20Biocartis NV: Press news Biocartis Group NV: Biocartis Announces Ten Idylla Studies to be Published at Virtual AMP (US) Annual Meeting1
10.11.20Biocartis NV: Press news Biocartis Group NV: Biocartis Announces CE-marking of its Fully Automated Idylla SARS-CoV-2 Test4
03.11.20Biocartis NV: Press news Biocartis Group NV: Biocartis Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness2
03.11.20Biocartis NV: Press news Biocartis Group NV: Biocartis and GeneproDx To Collaborate on Fully Automated ThyroidPrint test on Idylla3
29.10.20Biocartis NV: Press news Biocartis Group NV: Biocartis and Exact Sciences Agree to End Collaboration Due to Changed Market Circumstances11
29.10.20Biocartis NV: Press news Biocartis Group NV: Update on the partnership with Exact Sciences8
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3